Compare Salesforce Inc (CRM) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Novartis AG — how do they compare? Salesforce Inc trades at $192.51 (market cap $161.73B), while Novartis AG trades at $152.9 (market cap $295.37B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| CRM | NVS | |
|---|---|---|
Market Cap | $161.73B | $295.37B |
Sector | Technology | Health |
52-Week High | $266.23 | $168.62 |
52-Week Low | $150.12 | $119.31 |
Enterprise Value | $191.77B | $336.69B |
Dividend Yield | 0.89% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $197.51, up 2.47% with strong technical momentum as the stock approaches resistance at $200. The company demonstrates robust fundamentals with consistent earnings beats, posting Q1 2026 EPS of $3.88 versus $3.13 expected, and maintains impressive profitability with 77.64% gross margins. Revenue growth accelerated to $37.9B in 2025 with net income reaching $6.2B, while analyst sentiment remains overwhelmingly positive with 76% buy ratings.
Outlook remains favorable with AI-driven growth catalysts and a $230.61 consensus price target offering 17% upside potential. Key risks include competitive pressures in the SaaS sector and market volatility from AI disruption concerns. The stock presents a compelling opportunity given its Rule of 44 performance metrics and strong cash flow generation of $13.1B from operations.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
